Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

@article{Karp1987OralNF,
  title={Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.},
  author={Judith E. Karp and William G. Merz and C. S. Hendricksen and B E Laughon and T Redden and B J Bamberger and John G. Bartlett and Rein Saral and P. J. Burke},
  journal={Annals of internal medicine},
  year={1987},
  volume={106 1},
  pages={1-7}
}
We evaluated the effect of norfloxacin, 400 mg given orally every 12 hours, on the prevention of bacterial infections in 68 adult patients who had acute leukemia throughout prolonged courses of granulocytopenia (median, 32 days). Gram-negative infections were documented in 13 of the 33 patients receiving placebo, but only in 4 of the 35 patients receiving norfloxacin; no effect on the frequency of gram-positive or fungal infections was noted. Norfloxacin administration resulted in the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Similar Papers

Loading similar papers…